The resolution comes two months after the health regulator said there was no longer a shortage of Eli Lilly's weight-loss and diabetes drugs. All doses of Novo's diabetes treatment Ozempic and ...

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

Dr. Philip A. Chan joined GoLocal to discuss the new wave of weight loss drugs and their implications for fighting obesity as ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and ...

Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...